Gerhardt T C, Goldstein R M, Urschel H C, Tripp L E, Levy M F, Husberg B S, Jennings L W, Gonwa T A, Klintmalm G B
Transplantation Services, Baylor University Medical Center, Dallas, Texas 75246, USA.
Transplantation. 1996 Oct 27;62(8):1060-3. doi: 10.1097/00007890-199610270-00005.
Due to the significant increase in the number of patients with alcoholic liver cirrhosis being referred for liver transplantation, studies to determine recidivism rates and influential factors affecting those rates have become increasingly crucial. Between 12/85 and 12/91, 67 patients diagnosed with alcohol related end-stage liver disease underwent orthotopic liver transplantation at Baylor University Medical Center. A 3-8 year follow-up study was conducted wherein surviving patients were contacted by phone to evaluate subsequent alcohol consumption following transplantation (with the exception of two patients whose primary physicians were contacted). Of the 67 patients transplanted, 18 had expired, 7 were alive but unavailable, and 1 had been lost to follow-up. Of the remaining 41 patients interviewed, 21 had remained abstinent, while the other 20 had returned to some form of drinking. Of patients with less than 6 months of pretransplant abstinence, only 30% remained abstinent, while the other 70% had resumed drinking. Regarding patients with at least 6 months of pretransplant abstinence, 58% had remained abstinent, while the other 42% had resumed drinking. In both groups, nearly 1/3 of those who had admitted to posttransplant drinking reported themselves as again abstinent and recommitted to sobriety when interviewed. In conclusion, 49% of patients interviewed had resumed some type of drinking following transplantation-- however, this appears not to have affected compliance or survival potential. Only 2 (4.8%) of the 41 patients interviewed had returned to excessive drinking. Thus, our findings support the use of orthotopic liver transplantation for patients with alcohol related end-stage liver disease.
由于转诊接受肝移植的酒精性肝硬化患者数量显著增加,因此确定酗酒复吸率以及影响这些比率的相关因素的研究变得愈发关键。在1985年12月至1991年12月期间,67名被诊断患有酒精性终末期肝病的患者在贝勒大学医学中心接受了原位肝移植。进行了一项为期3至8年的随访研究,通过电话联系存活患者,以评估移植后其后续饮酒情况(有两名患者联系了他们的主治医生,除此之外均为电话联系)。在接受移植的67名患者中,18人已经去世,7人存活但无法联系到,1人失访。在其余接受访谈的41名患者中,21人保持戒酒,而另外20人又恢复了某种形式的饮酒。移植前戒酒时间少于6个月的患者中,只有30%保持戒酒,而另外70%又重新开始饮酒。对于移植前至少戒酒6个月的患者,58%保持戒酒,而另外42%又重新开始饮酒。在两组中,几乎1/3承认移植后饮酒的患者在接受访谈时表示自己又再次戒酒并重新致力于保持清醒。总之,接受访谈的患者中有49%在移植后又恢复了某种形式的饮酒——然而,这似乎并未影响依从性或生存潜力。在接受访谈的41名患者中,只有2人(4.8%)又恢复了过度饮酒。因此,我们的研究结果支持对酒精性终末期肝病患者使用原位肝移植。